Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI-4500
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BI-4500 (also known as Complex I Modulator or CIM) is a novel, potent, and selective small-molecule mitochondrial complex I (NADH:ubiquinone oxidoreductase) reactive oxygen species (ROS) modulator developed by Boehringer Ingelheim. Unlike classical complex I inhibitors (such as rotenone) which impair oxidative phosphorylation and ATP production, BI-4500 selectively targets and suppresses superoxide production from the complex I ubiquinone-binding site (IQ) during reverse electron transport (RET) while preserving normal complex I-dependent mitochondrial respiration and cellular energy production. It has been investigated preclinically for its renoprotective properties in diabetic kidney disease (DKD), for its potential therapeutic benefits in metabolic-dysfunction-associated steatohepatitis (MASH), and for improving muscle regeneration in aging muscle.
- Other names
- BIMCIMComplex I ModulatorComplex I ROS modulatormitochondrial complex I modulator
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on BI-4500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI-4500.